Managing severe asthma exacerbations in children

Suja J. Nair, Michelle M. Cloutier

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

In children with severe asthma exacerbations, the best clinical indicators of severe airflow obstruction are the use of accessory muscles of respiration, severe dyspnea, and pulsus paradoxus. Patients with obvious signs of worsening respiratory distress should have immediate arterial blood gas sampling. Standard therapies include supplemental oxygen, 2 to 4 L/min by nasal cannula or 6 to 8 L/min by simple face mask; continuous nebulization of a β2-agonist; and systemic corticosteroids (oral administration is appropriate if the child does not have nausea or vomiting). Intravenous β2-agonists may be considered in patients with respiratory deterioration who do not respond to nebulized β2-agonist therapy. The addition of ipratropium in the emergency department (ED) may improve pulmonary function and obviate the need for hospitalization. Intravenous magnesium may be a safe adjunct to therapy for children who do not respond adequately to standard therapy in the ED.

Original languageEnglish (US)
Pages (from-to)12-21
Number of pages10
JournalJournal of Respiratory Diseases - For Pediatricians
Volume5
Issue number1
StatePublished - Jan 2003

Fingerprint

Asthma
Hospital Emergency Service
Ipratropium
Therapeutics
Masks
Dyspnea
Magnesium
Nausea
Vomiting
Oral Administration
Pulse
Adrenal Cortex Hormones
Respiration
Hospitalization
Gases
Oxygen
Muscles
Lung

Keywords

  • Chest radiographs showing pneumothorax, pneumomediastinum, and atelectasis
  • Risk factors for fatal asthma Pathophysiologic effects on the lungs
  • The relationship between arterial blood gases and the degree of airway obstruction

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine

Cite this

Managing severe asthma exacerbations in children. / Nair, Suja J.; Cloutier, Michelle M.

In: Journal of Respiratory Diseases - For Pediatricians, Vol. 5, No. 1, 01.2003, p. 12-21.

Research output: Contribution to journalArticle

@article{c71e5f6a224e4deea6b8cb49276fff2b,
title = "Managing severe asthma exacerbations in children",
abstract = "In children with severe asthma exacerbations, the best clinical indicators of severe airflow obstruction are the use of accessory muscles of respiration, severe dyspnea, and pulsus paradoxus. Patients with obvious signs of worsening respiratory distress should have immediate arterial blood gas sampling. Standard therapies include supplemental oxygen, 2 to 4 L/min by nasal cannula or 6 to 8 L/min by simple face mask; continuous nebulization of a β2-agonist; and systemic corticosteroids (oral administration is appropriate if the child does not have nausea or vomiting). Intravenous β2-agonists may be considered in patients with respiratory deterioration who do not respond to nebulized β2-agonist therapy. The addition of ipratropium in the emergency department (ED) may improve pulmonary function and obviate the need for hospitalization. Intravenous magnesium may be a safe adjunct to therapy for children who do not respond adequately to standard therapy in the ED.",
keywords = "Chest radiographs showing pneumothorax, pneumomediastinum, and atelectasis, Risk factors for fatal asthma Pathophysiologic effects on the lungs, The relationship between arterial blood gases and the degree of airway obstruction",
author = "Nair, {Suja J.} and Cloutier, {Michelle M.}",
year = "2003",
month = "1",
language = "English (US)",
volume = "5",
pages = "12--21",
journal = "Journal of Respiratory Diseases",
issn = "0194-259X",
publisher = "Cliggott Publishing Co.",
number = "1",

}

TY - JOUR

T1 - Managing severe asthma exacerbations in children

AU - Nair, Suja J.

AU - Cloutier, Michelle M.

PY - 2003/1

Y1 - 2003/1

N2 - In children with severe asthma exacerbations, the best clinical indicators of severe airflow obstruction are the use of accessory muscles of respiration, severe dyspnea, and pulsus paradoxus. Patients with obvious signs of worsening respiratory distress should have immediate arterial blood gas sampling. Standard therapies include supplemental oxygen, 2 to 4 L/min by nasal cannula or 6 to 8 L/min by simple face mask; continuous nebulization of a β2-agonist; and systemic corticosteroids (oral administration is appropriate if the child does not have nausea or vomiting). Intravenous β2-agonists may be considered in patients with respiratory deterioration who do not respond to nebulized β2-agonist therapy. The addition of ipratropium in the emergency department (ED) may improve pulmonary function and obviate the need for hospitalization. Intravenous magnesium may be a safe adjunct to therapy for children who do not respond adequately to standard therapy in the ED.

AB - In children with severe asthma exacerbations, the best clinical indicators of severe airflow obstruction are the use of accessory muscles of respiration, severe dyspnea, and pulsus paradoxus. Patients with obvious signs of worsening respiratory distress should have immediate arterial blood gas sampling. Standard therapies include supplemental oxygen, 2 to 4 L/min by nasal cannula or 6 to 8 L/min by simple face mask; continuous nebulization of a β2-agonist; and systemic corticosteroids (oral administration is appropriate if the child does not have nausea or vomiting). Intravenous β2-agonists may be considered in patients with respiratory deterioration who do not respond to nebulized β2-agonist therapy. The addition of ipratropium in the emergency department (ED) may improve pulmonary function and obviate the need for hospitalization. Intravenous magnesium may be a safe adjunct to therapy for children who do not respond adequately to standard therapy in the ED.

KW - Chest radiographs showing pneumothorax, pneumomediastinum, and atelectasis

KW - Risk factors for fatal asthma Pathophysiologic effects on the lungs

KW - The relationship between arterial blood gases and the degree of airway obstruction

UR - http://www.scopus.com/inward/record.url?scp=0037255840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037255840&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0037255840

VL - 5

SP - 12

EP - 21

JO - Journal of Respiratory Diseases

JF - Journal of Respiratory Diseases

SN - 0194-259X

IS - 1

ER -